2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
复制标题
DOI：
10.1016/j.jacc.2011.08.023
复制
发表时间：
2011-11-01
影响因子：
24
通讯作者：
Society for Vascular Surgery
中科院分区：
文献类型：
--
作者：
Rooke TW;Hirsch AT;Misra S;Sidawy AN;Beckman JA;Findeiss LK;Golzarian J;Gornik HL;Halperin JL;Jaff MR;Moneta GL;Olin JW;Stanley JC;White CJ;White JV;Zierler RE;Society for Cardiovascular Angiography and Interventions;Society of Interventional Radiology;Society for Vascular Medicine;Society for Vascular Surgery
1.1.方法和证据综述2005年指南撰写委员会与工作组和其他专家一起审查了在ACC、AHA、欧洲心脏病学会、血管外科学会、介入放射学会和血管医学会的年度科学会议上提交的最新临床试验的结果，以及选定的其他数据/文章，以确定可能影响指南建议的那些试验和其他关键数据。根据上述标准/考虑，最近的试验数据和其他临床信息被认为足够重要，足以促使“ACC/AHA 2005年周围动脉疾病(下肢、肾、肠系膜和腹主动脉)患者管理指南”(2)的重点更新。由于血管疾病的临床研究和临床护理具有全球研究和国际临床护理的传统，我们努力使这一更新与跨大西洋社会关于周围动脉疾病管理的共识文件(TASC)和关于周围动脉疾病管理的社会间共识(TASC II)指导委员会指南的编写工作(3)相一致。为了向临床医生提供一组全面的数据，无论何时被认为合适或在发布时，指南中都提供了治疗或伤害所需的绝对风险差异和数量，以及可信区间(CI)和与相对治疗效果相关的数据，如优势比、相对风险、危险比(HR)，或发病率比。请参考《ACC/AHA 2005外周动脉疾病(下肢、肾、肠系膜和腹主动脉)患者管理指南》的全文版(2)或执行摘要(4)，以了解重点更新中未涵盖的临床领域的政策。在本次重点更新中修改的个别建议将纳入指南全文的未来修订和/或更新中。
1.1. Methodology and Evidence Review The results of late-breaking clinical trials presented at the annual scientific meetings of the ACC, AHA, European Society of Cardiology, Society for Vascular Surgery, Society of Interventional Radiology, and Society for Vascular Medicine, as well as selected other data/articles published through December 2010, were reviewed by the 2005 guideline writing committee along with the Task Force and other experts to identify those trials and other key data that may impact guideline recommendations. On the basis of the criteria/considerations noted above, recent trial data and other clinical information were considered important enough to prompt a focused update of the “ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)”(2). Because clinical research and clinical care of vascular disease have a global investigative and international clinical care tradition, efforts were made to harmonize this update with the Trans-Atlantic Inter-Society Consensus document on Management of Peripheral Arterial Disease (TASC) and the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Steering Committee guideline writing efforts (3).To provide clinicians with a comprehensive set of data, whenever deemed appropriate or when published, the absolute risk difference and number needed to treat or harm are provided in the guideline, along with confidence intervals (CIs) and data related to the relative treatment effects, such as odds ratio, relative risk, hazard ratio (HR), or incidence rate ratio. Consult the full-text version (2) or executive summary (4) of the “ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)” for policy on clinical areas not covered by the focused update. Individual recommendations modified in this focused update will be incorporated into future revisions and/or updates of the full-text guideline.